TP53 and neoplasm: One possibility is that other, more basic and still unidentified biologic alterations in TP53 mutated tumours might exert an even more important influence on clinical course, and that these could be active already before TP53 mutations become detectable, which may have implications for the ongoing efforts to target mutant TP53 with novel drugs [15].